Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

Billionaire Kumar Mangalam Birla on Thursday promised a massive investment and unveiled a new identity of the company. The ...